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Objective: The histological classiﬁcation of the World Health Organization (WHO), along with
improved imaging studies, provide relevant information for the management of parotid
carcinomas. However, the prognosis depends on factors other than histology and tumor
extension. This article evaluates the usefulness of a prognostic classiﬁcation of parotid
cancers, including these factors in patients in a hospital area.
Methods: A follow-up was conducted on 19 patients with parotid carcinomas, excluding lym-
phoid  tumors or intra-parotid metastases, between 1998 and 2012. The prognostic index was
obtained from the formulas proposed by Vander Poorten, with factors including age, tumor
size, lymph node involvement, skin invasion, facial nerve involvement, perineural growth
and margins of resection, before surgery (PS1) and after (PS2). Overall survival was related
to  5 years for each patient based on their inclusion in any of the 4 risk groups deﬁned.
Results: Risk stratiﬁcation based on the results Vander Poorten PS2 was distributed into Risk
Groups (GR) 1 (3 patients, 15.7%), 2 (5 patients, 26.3%), 3 (1 patient, 5.8%) and 4 (10 patients,
52.2%). The 6 patients who died during follow-up belonged to GR4. Only one of the 4 patients
belonging to GR4 has exceeded the 5-year survival up to the current time.
The comparison of the values that relate the pretreatment (PS1) and after treatment (PS2)
results showed overall survival in patients with PS1 < 4.5 and PS2 < 4.9, whereas mortality
was greater with indices of PS1 > 6.5 and PS2 > 7.7.
Conclusions: Vander Poorten index can be applied in hospital areas with small numbers of
parotid carcinomas. It enables a more accurate prognosis for individual patients.
©  2014 SECOM. Published by Elsevier España, S.L.U. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Clasiﬁcación  pronóstica  de  los  tumores  malignos  de  glándula  parótida
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Vander Poorten
r  e  s  u  m  e  n
Objetivo: La clasiﬁcación histológica de la Organización Mundial de la Salud (OMS) junto con
mejores estudios de imagen aportan información relevante para el manejo de los cánceres
de  parótida. Sin embargo, su pronóstico depende de otros factores diferentes de la histología
y  la extensión tumoral. El presente trabajo valora la utilidad de la clasiﬁcación pronóstica de
Vander Poorten creada en 1999 de los cánceres parotídeos que incluye todos estos factores
en  los pacientes de nuestro medio.
Métodos: Seguimiento de 19 pacientes con carcinomas de parótida distintos de tumores
linfoideos o metástasis intraparotídeas entre los an˜os 1998 y 2012. Se obtuvo su índice
pronóstico a partir de las fórmulas propuestas por Vander Poorten, que incluyen los fac-
tores de edad, taman˜o tumoral, afectación ganglionar, invasión cutánea, afectación del
nervio facial, crecimiento perineural y márgenes de resección, antes de la cirugía (PS1) y
después (PS2). Se relacionó la supervivencia global a los 5 an˜os de cada paciente a partir de
su  inclusión en alguno de los 4 grupos de riesgo deﬁnidos.
Resultados: La estratiﬁcación de riesgo de Vander Poorten según los resultados PS2 se dis-
tribuyó en grupos de riesgo (GR) 1 (3 pacientes, 15,7%), 2 (5 pacientes, 26,3%), 3 (un paciente,
5,8%) y 4 (10 pacientes, 52,2%). Los 6 pacientes que fallecieron durante el seguimiento
pertenecían al GR4. De los 4 supervivientes del GR4 solo uno ha superado el seguimiento de
5  an˜os.
La comparación de las medias que relacionan las variables de resultado pretratamiento
(PS1) y postratamiento (PS2) mostró una mejor supervivencia global en los pacientes con
valores de PS1 < 4,5 y PS2 < 4,9, mientras que la mortalidad fue mayor a partir de los índices
de  PS1 > 6,5 y PS2 > 7,7.
Conclusiones: El índice de Vander Poorten es aplicable en áreas hospitalarias con escaso
número de carcinomas de parótida. Permite establecer un pronóstico de supervivencia más
certero sobre pacientes individuales.
©  2014 SECOM. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access
bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Malignant tumors of the parotid gland are characterized by
a low incidence (1–3% of all head and neck cancers) and a
marked histopathological heterogeneity.1 Approximately 70%
of the malignant tumors of the major salivary glands are
located in the parotid glands.2
Initially, the diagnosis is clinical, and requires ﬁne-needle
aspiration biopsy (FNAB) to determine the nature of the tumor.
Computed tomography (CT) and magnetic resonance imaging
(MRI) are key elements in the anatomical study, preoperative
evaluation and determination of the extension.3
The treatment of choice is always parotidectomy, with
preservation of the facial nerve whenever possible.4,5 The
need for radiotherapy,6 chemotherapy or cervical lymph node
dissection will depend on the stage, aggressiveness and his-
tological type of the tumor.
At the present time, there is no standardized approach
to the management of cancer of the major salivary glands
because of the many  subtypes, each with a unique molecular
background and variable clinical behavior.7 Even so, locore-
gional control of the cancer is satisfactory and the most
common cause of treatment failure is the development of
distant metastasis.8 Although the control of the disease con-
tinues to be variable, it would be possible to predict the
prognosis in individual patients using multivariate analysis.
The ability to predict the prognosis in these cancers would
make it possible to know what course the disease will take.
The risk stratiﬁcation model proposed by Vander Poorten
et al.9 as a predictive index could prove to be useful, as it inter-
relates many  of the variables that inﬂuence prognosis and
survival in patients with parotid carcinomas: age at diagno-
sis, tumor size, lymph node involvement, skin invasion, facial
nerve involvement, perineural growth and resection margins.
In this approach, all these factors are examined before and
after the proposed treatment.
Methods
For this study, we  chose to use the prognostic index devised by
Vander Poorten et al.,4,9 which establishes 2 numerical values
to estimate the probability of survival according to the results
of the formulas, expressed as the prognostic score (PS) before
treatment (PS1) and afterwards (PS2).
In this case, we divided the results into 4 groups, going
from lower risk to higher based on the posttreatment scoring
system described by Vander Poorten et al.4,9 in their original
study: risk group [RG]1: <3.99; RG2: 3.99–4.80; RG3: 4.81–5.67
and RG4: >5.67. In accordance with the data obtained, the
numerical result was used to establish the prediction for
the population-based overall survival in our regional health
area among patients diagnosed from 1998 to 2012 and having
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Table 1 – Malignant tumors of the major salivary glands.
Malignant tumors of the major salivary glands (WHO, 2005)7
Acinic cell carcinoma
Mucoepidermoid carcinoma
Adenoid cystic carcinoma
Polymorphous low-grade adenocarcinoma
Epithelial-myoepithelial carcinoma
Clear cell carcinoma (not otherwise speciﬁed)
Basal cell adenocarcinoma
Sebaceous carcinoma
Sebaceous lymphadenocarcinoma
Cystadenocarcinoma
Low-grade cribriform cystadenocarcinoma
Mucinous adenocarcinoma
Oncocytic carcinoma
Salivary duct carcinoma
Adenocarcinoma (not otherwise speciﬁed)
Myoepithelial carcinoma
Carcinoma ex pleomorphic adenoma
Carcinosarcoma
Metastasizing pleomorphic adenoma
Squamous cell carcinoma
Small cell carcinoma
Large cell carcinoma
Lymphoepithelial carcinoma
Sialoblastoma
Malignant tumors of the major salivary glands, updated by the
World Health Organization (WHO) in 2005.
undergone a maximum follow-up of 5 years. We  also com-
pared the mean scores obtained with the Vander Poorten index
to relate the outcome variables, PS1 and PS2, to overall sur-
vival.
We conducted a retrospective cross-sectional study involv-
ing the patients in the area covered by our hospital (population
551,856) who  had been diagnosed with any of the malig-
nant parotid tumors included in the 2005 classiﬁcation of
the World Health Organization (WHO)7 (Table 1) and had
undergone surgery, surgery plus radiotherapy, or surgery plus
radiotherapy and chemotherapy. The patients also had to
have undergone proper clinical staging according to the 2010
TNM classiﬁcation of the American Joint Committee on Can-
cer (AJCC), where T refers to the size of the lesion, N to the
existence of cervical lymph node metastases and M to distant
metastases. We  excluded patients with malignant tumors of
the major salivary glands not located in the parotid gland, with
malignant parotid tumors not included in the 2005 WHO  clas-
siﬁcation (Table 1) or with nonepithelial parotid metastases,
as well as those who  did not meet the inclusion criteria.
The patients with parotid carcinomas diagnosed from 1998
to 2012 were identiﬁed by searching the database of the pathol-
ogy department of our hospital (Microsoft Excel). The clinical
review was carried out using electronic information systems
and electronic health records (Medicx, Medicx 3 and Diraya),
and resorting to the manual review of the medical records in
speciﬁc cases.
The statistical analysis for the descriptive study and multi-
variate comparison of arithmetic means was performed with
the Statistical Package for the Social Sciences (SPSS) software.
For the statistically signiﬁcant variables, both the hazard ratio
Table 2 – Vander Poorten prognostic indices.
PS1: 0.024A + 0.62P + 0.44T + 0.45N + 0.63S + 0.91F
PS2: 0.018A + 0.39T + 0.34N + 0.7S + 0.56F + 0.78PG + 0.65PM
The prognostic index of Vander Poorten et al.,4,9 calculated accord-
ing to the pretreatment (PS1) and posttreatment (PS2) scores,
depends on patient age, pain, TNM classiﬁcation, skin invasion,
facial nerve dysfunction, perineural invasion and surgical margin
status.
A: age; F: facial nerve dysfunction; N: clinical N classiﬁcation; P:
pain at presentation; PG: perineural invasion; PM: surgical margins;
S: skin invasion; T: clinical T classiﬁcation.
and its 95% conﬁdence interval were determined, with a p
value < 0.05.
The prognostic score for each patient was calculated in
accordance with the Vander Poorten indices.4,9 The PS1 pro-
gnostic score corresponded to the preoperative values and PS2
to the postoperative ﬁndings (Table 2).
Results
Of the 30 cases of malignant parotid tumor recorded in our
hospital from 1998 to 2012, we included the 19 patients who
had had carcinomas, excluding 6 lymphoid tumors and 5
parotid metastases.
The age range at diagnosis was 20–84 years, with a mean
age of 61.7 years and a standard deviation of 16.8. Eleven of
the 19 patients were men.
When the cancers were grouped according to the histolog-
ical classiﬁcation of malignant major salivary gland tumors
(WHO, 2005),7 there was a predominance of mucoepidermoid
carcinomas (36.8%) and of epidermoid carcinomas (26.3%),
which was surprising, as the latter are uncommon in our
patient population (Fig. 1).
At the time of diagnosis, pain was recorded in 6 patients
(31.6%), 42.1% presented with skin evasion, 4 patients (21.05%)
reported some degree of facial paresis or paralysis prior to
surgery and surgical margin involvement was observed in 11
(57.8%).
The distribution according to the 2010 TNM classiﬁcation
of the AJCC differed depending on whether it was clinical or
histopathological (Table 3). According to clinical TNM staging,
2 patients (10.5%) were T1, 7 (36.8%) T2, 6 (31.5%) T3 and 4
(21.2%) T4. In 12 cases (61.5%), there were no lateral cervi-
cal lymph node metastases (N0); 3 patients (15.7%) were N1
and 4 (21.2%) were N2). Distant metastases were recorded in
2 patients (10.5%). In the pathological TNM, 2 patients (10.5%)
were T1, 5 (26.35%) T2, 5 (26.35%) T3 and 7 (36.8%) T4. Twelve
patients (61.5%) were N0, 3 (15.7%) were N1 and 4 (21.2%) were
N2. Distant metastases were found in 2 patients (10.5%).
A total of 17 patients (89.5%) underwent total or partial
parotidectomy and adjuvant radiotherapy (Table 3) with cura-
tive intent; 6 of them (35.2%) had some type of postoperative
facial nerve dysfunction. At the time of writing, 1 patient (5.8%)
was receiving palliative treatment with chemotherapy due
to inoperable disease recurrence. The 2 patients (10.5%) who
had not undergone either surgical treatment or radiotherapy
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Table 3 – Classiﬁcation, outcome and characteristics of the study patients.
Patient
no.
Type of carcinoma TNM
(clinical)
TNM
(histological)
Clinical
stage
Histological
grade
PS1  PS2 Risk
group (RG)
Treatment Survival
1 Acinic cell carcinoma T2N0M0 T2N0M0 II II 3.97 4.45 2 Surgery + RT Yes
2 Mucoepidermoid carcinoma T3N1M0 T4N1M0 III IV 6.11 6.92 4 Surgery + RT Yes
3 Adenocarcinoma T3N0M0 T3N0M0 III III 5.94 8.04 4 Surgery + RT No
4 Acinic cell carcinoma T2N0M0 T2N0M0 II II 4.33 4.38 2 Surgery + RT Yes
5 Epidermoid carcinoma T4N2M0 T4N2M0 IV IV 7.3 7.83 4 Surgery + RT No
6 Mucoepidermoid carcinoma T2N1M0 T3N1M0 III III 6.32 6.67 4 RT No
7 Mucoepidermoid carcinoma T2N0M0 T2N0M0 II II 4.4 4.77 2 Surgery + RT Yes
8 Cystadenocarcinoma T4N1M1 T4N1M1 IV IV 7.75 8.13 4  RT + CT No
9 Large cell carcinoma T3N2M0 T3N2M0 IV IV 5.88 8.08 4 Surgery + RT No
10 Epidermoid carcinoma T3N0M0 T4N0M0 III IV 5.03 5.35 3 Surgery + RT Yes
11 Salivary duct carcinoma T2N2M0 T2N2M0 IV IV 6.26 7.97 4 Surgery + RT No
12 Epidermoid carcinoma T3N0M0 T3N0M0 III III 4.55 4.6 2 Surgery + RT Yes
13 Epidermoid carcinoma T4N0M1 T4N0M1 IV IV 5.28 6.09 4 Surgery + RT + CT Yes
14 Epidermoid carcinoma T3N2M0 T4N2M0 IV IV 5.72 5.87 4  Surgery + RT Yes
15 Mucoepidermoid carcinoma T4N0M0 T4N0M0 IV IV 5.27 6.67 4 Surgery + RT Yes
16 Mucoepidermoid carcinoma T1N0M0 T1N0M0 I I 3.08 3.44 1 Surgery + RT Yes
17 Mucoepidermoid carcinoma T1N0M0 T1N0M0 I I 3.3 3.55 1 Surgery + RT Yes
18 Myoepithelial carcinoma T2N0M0 T2N0M0 II II 3.75 3.94 1 Surgery + RT Yes
19 Mucoepidermoid carcinoma T2N0M0 T3N0M0 II III 3.8 4.37 2 Surgery + RT Yes
CT: chemotherapy; RT: radiotherapy.
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Table 4 – Results applied to Vander Poorten prognostic
indices.
Survival Sample Mean SD
Pretreatment (PS1)
Yes 13 4.5 0.93
No 6 6.5 0.76
Posttreatment (PS2)
Yes 13 4.9 1.13
No 6 7.7 0.55
The application of the Vander Poorten indices enabled the calcula-
tion of the pretreatment (PS1) and posttreatment (PS2) scores. The
table shows the relationship between the mean scores and survival.
PS: prognostic score; SD: standard deviation.
Survivors Nonsurvivors
Survival
Pretreatment
score
Posttreatment
score
3
4
6
7
8
9
95
%
 C
I
5
Figure 3 – Linear correlation representing survival. There is
a linear correlation between the scores in the prognostic
indices of Vander Poorten et al. and survival. The higher the
score, the higher the probability of death and vice versa.
outcome variables (PS1) and the posttreatment ﬁndings (PS2)
to patient survival. We  found that there were differences in
the survival rate that favored those patients with PS1 < 4.5 and
PS2 < 4.9 over those with PS1 > 6.5 and PS2 > 7.7 (Table 4). More-
over, there was a linear correlation between the results (Fig. 3),
since the patients with the lowest scores survived, whereas an
increase in the score was accompanied by a higher mortality
rate.
Discussion
In 1991, Frankenthaler et al.10 conducted studies on the
prognosis of malignant parotid tumors. They carried out a
retrospective analysis of 178 patients, 59.9% of whom had
been treated surgically, and the remaining 40.1% had under-
gone surgery and radiotherapy. The mean follow-up was 7.5
years from the time of diagnosis. They concluded that the
prognosis depended on the tumor stage, tumor grade, his-
tological type, lymph node and perineural invasion, tumor
size, extension beyond the parotid fascia, resection margin
status, patient age and the presence of metastases. On  the
basis of that study, measures were proposed for the anal-
ysis of the optimal surgical procedure and the reasons for
choosing combined treatment. Hocwald et al.11 established
the prognostic factors for major salivary gland carcinomas
and determined the 5-year survival in a retrospective study
of 78 patients. All of the patients had been treated surgically,
regardless of the tumor type; 56% had also received radiothe-
rapy and 13%, chemotherapy. The 5-year disease-free survival
was 65%. On the examination of the clinical and histopatho-
logical outcomes, they observed that the presence of cervical
lymph node metastases and perineural invasion were fac-
tors indicative of poor prognosis, independent of the survival.
They suggested that adjuvant chemotherapy and radiotherapy
may improve survival. In their study, “Prognostic indicators for
malignant tumors of the parotid gland”,12 Harbo et al. estab-
lished a prognostic relationship between the tumors, their
stage and the histological classiﬁcation. They carried out a
retrospective study in a sample of 152 patients with parotid
carcinomas, measuring the overall survival 5 years after the
diagnosis of the disease (50%). They found statistically signif-
icant differences in survival depending on the stage, favoring
those patients in whom the disease was less advanced, with
a survival rate of 65% in stage I and of 50% in stage II, whereas
in stage IV, it was reduced to 9%. The prognosis for survival in
histologically well differentiated tumors (52%) was also bet-
ter than that associated with poorly differentiated lesions
(19%). The authors concluded that the TNM system was a
good predictor of the results of treatment and that the use of
a combination of clinical and histological factors would aid
in the design of treatment strategies. In 2005, members of
the department of otorhinolaryngology of Hospital Gregorio
Maran˜ón in Madrid, Spain, conducted a study13 of the out-
comes of the diagnosis and treatment of parotid cancer in their
hospital between 1991 and 2002. They reported an overall 5-
year survival in their patient population of 56% (60% in our
series) – 68% for stages I and II and 43% for stages III and IV –
and concluded that, in this disease of low incidence and high
mortality, staging and histological study were highly valuable
prognostic factors.
The importance of the prognostic index described by
Vander Poorten et al.4,9 lies in the combination of multi-
ple variables including age, tumor size, perineural invasion,
resection margin involvement, pain, etc. These predictive fac-
tors had never been combined to establish a given prognosis.
The incorporation of a tool that related these adverse factors
would improve the prediction of overall survival in patients
with parotid carcinomas. The prognostic score (PS) classiﬁed
patients according to 4 subgroups ranging from lower to higher
risk. In the subgroups formed on the basis of the postoperative
prognostic score, the 5-year disease-free survival rate ranged
between 95% (RG1) and 42% (RG4). Thus, the Vander Poorten
prognostic score4,9 provided a system for grouping variables
as an aid in the treatment and the prediction for survival
of patients with parotid carcinomas. The study of Takahama
et al.14 compared the prognostic scores and risk stratiﬁcation
of Vander Poorten et al.4,9 with those of Carrillo et al.15 The
authors pointed out that proponents tend to conﬁrm the valid-
ity of their own models, but that other researchers are less
successful in doing so. Takahama et al.14 found that the group
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of Carrillo et al. was more  similar to theirs, and concluded
that the scores calculated with the system of Carrillo et al.
generated more  distinct survival curves, although the deter-
mination of the groups with a more  favorable prognosis was
not easy with either of these scoring systems. Therefore, the
results were not totally reproducible in their group of patients.
The ﬁndings of our study ﬁt the prognoses resulting from
the trial reported by Vander Poorten et al.4,9 Although we are
aware of the statistical limitations inherent in a small sample
(19 patients), when our results were stratiﬁed according to sub-
group, we  observed that all 6 (100%) of the patients who had
died belonged to RG4 (PS > 5.67), and that there may be more
deaths in that group, as 3 of the remaining 4 patients had not
yet completed 5 years of follow-up at the time of writing.
A study of the comparison of the means yielded a math-
ematical relationship that showed that those patients with a
PS1 < 4.5 or a PS2 < 4.9 have greater probabilities of survival that
those with a PS1 > 6.5 or a PS2 > 7.7, either of which consider-
ably reduces their life expectancy. Although this is merely a
numerical datum in a small sample size, these results could
be taken into account in the evaluation of survival rates.
Our sample group ﬁts description of the clinical and
histopathological characteristics of malignant parotid tumors,
as well as the distribution by sex and age, the TNM and the
treatment received.
The key point that determines a poor prognosis for patient
outcome according to Vander Poorten et al.9 is recurrence of
the disease at 5 years of survival. Of the 19 patients in our
study, 6 died; of the latter group, only 1 was still alive 5 years
after being diagnosed. For this reason, we have considered the
factor “death” as a key point of our study, taking into account
the fact that all of the deaths were due to the patient’s cancer.
Conclusions
Despite the heterogeneity of parotid cancer in terms of the his-
tological features and risk factors, the Vander Poorten index
enables the accurate risk stratiﬁcation, according to individ-
ual prognoses, of parotid cancer patients in hospitals located
in health areas with a low incidence or that are not referral
centers for the management of this disease.
Studies need to be carried out with a sufﬁcient number of
patients to validate our ﬁnding that the comparison of the
mean scores corresponding to PS1 and PS2 enabled us to make
ﬁner distinctions when using the Vander Poorten prognostic
index.
Ethical  disclosures
Protection of human and animal subjects. The authors
declare that no experiments were performed on humans or
animals for this study.
Conﬁdentiality of data. The authors declare that they have fol-
lowed the protocols of their work center on the publication of
patient data.
Right to privacy and informed consent. The authors declare
that no patient data appear in this article.
Conﬂicts  of  interest
The authors declare they have no conﬂicts of interest.
r  e  f  e  r  e  n  c  e  s
1. Tsai HH. Parotid neoplasms: diagnosis, treatment and
intraparotid facial nerve anatomy. J Laryngol Otol.
2002;116:359–62.
2. Van Eycken L. Cancer incidence in Belgium 2004–2005. Head
Neck Cancer. 2008:41.
3. Spiro RH. Changing trends in the management o salivary
tumors. Seming Surg Oncol. 1995;11:240–5.
4. Vander Poorten VL, Valm AJ, Hilgers FJ. Management of cancer
of  the parotid gland. Curr Opin Otolaryngol Head Neck Surg.
2002;10:134–44.
5. Granell J, Sánchez-Jara JL, Gavilanes J, Velasco MJ, Collazo T,
Herrero J, et al. Manejo de la enfermedad quirúrgica de la
glándula parótida: revisión de 54 casos. Acta Otorrinolaringol
Esp. 2010;61:189–95.
6. North CA, Lee D, Piantadosi S, Zahurak M,  Johns ME.
Carcinoma of the major salivary glands treated by surgery or
surgery postoperative radiotherapy. Int J Radiat Oncol Biol
Phys. 1990;18:1319–26.
7. Barnes L, Evesnon J, Reichart P, Sidranski D. World Health
Organization classiﬁcation of tumours. In: Barnes L, Evesnon
J, Reichart P, Sidranski D, editors. Pathology and genetics of
head and neck tumours. 2005. p. 210.
8. Regis de Brito Santos I, Kowalski LP, Cavalcante de Araujo V,
Flavia Logullo A, Magrin J. Multivariante análisis of risk factors
for  neck metastases in surgically treated parotid carcinomas.
Arch Otolaryngol Head Neck Surg. 2001;127:56–60.
9. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM,
Kens RB, et al. The development of a prognostic score for
patients with parotid carcinoma. Cancer. 1999;85:2057–67.
10. Frankenthaler RA, Luna M, Lee SS, Ang KK, Byers RM,
Guillamondegui OM, et al. Prognostic variables in parotid
gland cancer. Arch Otolaryngol Head Neck Surg.
1991;117:1251–6.
11. Hocwald E, Korkmaz H, Yoo G. Prognostic factors in major
salivary gland cancer. Laryngoscope. 2001;111:1434–9.
12. Harbo G, Bundgaard T, Pedersen D, Sogaard H, Overgaard J.
Prognostic indicators for malignant tumors of the parotid
gland. Clin Otolaryngol. 2002;27:512–6.
13. Rodríguez Paramás A, Lendoiro Otero C, González García A,
Souviron Encabo R, Scola Yurrita B. Tumores malignos de
parótida. Acta Otorrinolaringol Esp. 2005;56:211–4.
14. Takahama A, Sanabria A, Melo G, Paes O, Kowalski L.
Comparasion of 2 prognostic scores for patients with parotid
carcinoma. Head & Neck. 2009;31:1188–95.
15. Carrillo JV, Ramírez-Ortega M, Cano A, Ochoa-Carrillo F,
On˜ate-Ocan˜a L. Multivariate prediction of de probability of
recurrence in patients with carcinoma of the parotid gland.
Cancer. 2007;109:2043–51.
